| Expression pattern: |
UP |
| Associated gene: |
METTL3, KRAS, AAGAB |
| Associated microRNA: |
miR-216b-5p |
| Biological function: |
circ_0000620 promotes malignant behavior of LUAD cells, including cell proliferation, activity and migration, reduces apoptosis, and decreases cisplatin sensitivity; knockdown of circ_0000620 inhibits tumor growth and proliferation in vivo. |
| Molecular mechanism: |
METTL3-mediated m6A methylation promotes circ_0000620 stability and expression; circ_0000620 acts as a sponge for miR-216b-5p and regulates KRAS to influence apoptosis and cisplatin sensitivity. |
| Biological pathway or process: |
apoptosis (inhibits); proliferation (promotes); migration (promotes); drug resistance (promotes); chemoresistance (promotes); ceRNA regulation (other); m6A modification (other); other pathway/process (promotes) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; MeRIP / MeRIP-seq; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Wound Healing Assay; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; Clinical Sample Validation; Bioinformatics Analysis |
| Clinical significance: |
circ_0000620 is closely associated with cisplatin sensitivity in LUAD and may represent a potential therapeutic target for overcoming cisplatin resistance. |
| Description: |
circ_0000620 is upregulated in LUAD tissues and cell lines and functions as an oncogenic circRNA that promotes proliferation, migration and cisplatin resistance while inhibiting apoptosis. Mechanistically, METTL3-mediated m6A modification increases circ_0000620 stability, and circ_0000620 sponges miR-216b-5p to regulate KRAS signaling, thereby modulating LUAD cell apoptosis and cisplatin sensitivity. |
| Confidence score: |
0.8496 |